Alex Nepogodiev

Global marketing at Elixir Medical. Opinions are my own.

[Elixir Medical Corp @ElixirMed]

A critical moment for PCI!

Researchers presented the latest data – 4 years after the procedure – from the BIOADAPTOR RCT at #EuroPCR2026, comparing DynamX bioadaptor to a contemporary drug-eluting stent.

The big news:
66% reduction in target lesion failure (TLF) for DynamX bioadaptor compared to DES.

We’re excited to see the impact of the bioadaptor’s innovative unlocking technology on patient outcomes. The incidence curve of major adverse cardiac events in the years after PCI really is flattening.

#EuroPCR #DynamX #Bioadaptor #RCT #ClinicalData #Cardiology

Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States)
law to investigational use.

PMN 2475 Rev A

[TCTMD @TCTMD]

Unlocking Coronary Implant Impressive at 4 Years: BIOADAPTOR RCT https://t.co/97czjET2XL

[Elixir Medical Corp @ElixirMed]

Join us at the DGK Annual Meeting 2026.

📅 April 9, 2026
📍 Congress Center Rosengarten
Rosengartenplatz 2 - 68161Mannheim

Elixir Medical will participate in two focused sessions addressing challenges in contemporary PCI, featuring #LithiX #IVL and bioadaptive angioplasty with #DynamX Coronary Bioadaptor System.

🔹 Session 1
NEW APPROACHES TO OPTIMIZING PCI RESULTS
13:00 – 14:30
Room 15

Faculty: @GaedeLuise & @tommasoggori , Maren Weferling, @HolgerNef, @NikosWerner, Christoph Liebetrau

🔹 Session 2
Bioadaptor live-in-the-box case: Bifurcation – PCI
08:00 – 09:30
Room 22

Operator: Alexander Ghanem

Join to learn how our versatile #LithiX #IVL optimizes stent expansion regardless of calcium morphology¹ and how #Bioadaptor significantly reduces TLF rate compared to #PCI Standard of care².
These sessions will bring together innovative technologies, clinical evidence, and real-world insights to support decision-making in complex coronary interventions.

#DGK2026 #PCI #Cardiology #ElixirMedical #LithiX #IVL #DynamX #Bioadaptor

1. S. Verheye et. al. PINNACLE l EuroIntervention 2026;22:255-264
2. D. Elinge et. aL. INFINITY-Swedeheart 12 months. The Lancet 2024

The LithiX™ HC-IVL system and the DynamX® Coronary Bioadaptor System are CE mark approved and are not available for sale in the United States.

The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States.

Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use.

PMN 2420 Rev A

[Umberto Barbero @BarberoUmberto]

💪🏼Extreme hybrid revascularization for this LAD CTO in a 45 yo guy after LIMA failure:
- prox: short DES for optimal scaffolding
- mid: long Bioadaptor #DynamX by @ElixirMed to preserve vessel physiology
- dist: long DCB to avoid additional metal

#CTO #CHIP #PCI

[Marek Radomski @MarekRadomski71]

#LithiX #lithotripsy #Calcified #PCI #CHIP first case with LithiX balloon, 66yo male, borderline lesion in prox LAD but meets PREVENT criteria in IVUS. 12 inflations of LithiX in prox LAD followed by 2 stents and postdilatation with MC balloon

[Umberto Barbero @BarberoUmberto]

Severely tortuous, heavily calcified RCA successfully managed with a 🎈-based strategy with the @ElixirMed Lithix balloon allowed safe, efficient PCI with optimal expansion and final result. Nice case made reality together with Delio Tedeschi and @skat_ct live at #CTOhighlights

[I.H.Tanboga, MD, PhD @ihtanboga]

https://t.co/2TJJr9MwFV

[Davide Capodanno @DFCapodanno]

Intravascular lithotripsy is not just a matter of sonic waves. This study (PINNACLE-I) evaluates the LithiX lithotripsy device, which employs a Hertzian contact mechanism to fracture calcium while minimizing injury to surrounding soft tissue, without the need for an external energy source. https://t.co/hEGOLDgRVE

[EuroIntervention @EuroInterventio]

The novel LithiX Hertz Contact IVL catheter fractures coronary calcium via a unique Hertz contact mechanism—no external energy source required. Early outcomes show high procedural success, >90% calcium fractures, and optimal stent expansion across diverse morphologies.
https://t.co/TmAFP3H1Vv

@valeriaparadies @ZMehmedbegovic @mc_morice

[REC Publications @RevEspCardiol]

The LithiX lithotripsy system for the treatment of severe coronary calcification: early real-world experience #REC #Aheadofprint @JuradoRomanAl @ignamatsant https://t.co/racBvyvGcj

[Elixir Medical Corp @ElixirMed]

How do we overcome the challenge of calcium modification? At GRCI2025, Frédéric Bouisset, Charlotte Trouillet, Pierre Robert, and Benoît Lattuca shared their experiences with LithiX HC-IVL.

They discussed the importance of calcium modification in clinical outcomes and detailed the versatility, deliverability, and safety of LithiX as it was used to achieve outstanding results in lesion preparation in two illustrative cases:
• A severely calcified lesion with nodular calcium
• A long, eccentric, heavy calcified lesion

Check out the full recording to see the OCT and IVUS results for yourself!
Watch here: https://t.co/TMgxKipK8y

#LithiX #Lithotripsy #GRCI2025 #PCI #ElixirMedical

The LithiX™ HC-IVL system is CE mark approved and is not available for sale in the United States.

CAUTION: Case studies shown are based on individual experiences and results may vary. Results depend on a variety of factors, including patient history, severity of condition, and compliance with instructions. Elixir Medical does not claim that these results demonstrate the safety and effectiveness of the device.

PMN 2381 Rev A

[Elixir Medical Corp @ElixirMed]

Stunning All-Comers IVL Outcomes.

Outcomes of the MY-IVL all-comers clinical study showed versatility of LithiX Hertz Contact (HC) Intravascular Lithotripsy (IVL) to safely fragment diverse calcium morphologies in complex patient population resulting in optimal stent expansion.

Led by study co-PIs Dr. Tamil Selvan Muthusamy and Dr. Ali Rosli at Cardiac Vascular Sentral Kuala Lumpur Hospital (CVSKL), this clinical study involved:

• 64% ACS clinical presentation
• 88% severe lesion calcification
• 41% eccentric calcific lesions

To learn more: https://t.co/vbkGRoyol3

To review the complete MY-IVL Clinical Study outcomes presentation: https://t.co/pupJLeRkII

LithiX Hertz Contact Lithotripsy System is CE Mark approved and not for sale in the U.S.

[Cardiac Interventions Today @cardiacinterv]

Elixir’s LithiX HC IVL System Data Presented From Real-World Study of Calcified Coronary Lesion Treatment https://t.co/RWJEsmhlok @ElixirMed

[TVP3 Białystok @TvpBia]

W Szpitalu Wojewódzkim im. Kardynała Stefana Wyszyńskiego w Łomży po raz pierwszy w województwie podlaskim wykonano dwa zabiegi litotrypsji wewnątrznaczyniowej (IVL) z wykorzystaniem balonu LithiX. https://t.co/Zm1knnJ5ug

[CRT Meeting @CRT_meeting]

The Bioadaptor implant maintains safe long-term outcomes, compared with contemporary DES, for the treatment of clinically complex, high-risk patients with #ACS, an analysis of the INFINITY-SWEDEHEART trial shows. Read more from #TCT2025 on #CRTonline. https://t.co/nNSOFkLVTg

[Cardiology Today @CardiologyToday]

A bioadaptor implant adaptable to vessel physiology was linked to less target lesion failure and target vessel failure compared with a drug-eluting stent between 6 months and 2 years, researchers reported at #TCT2025.

@tctconference @crfheart @ElixirMed

https://t.co/DpUf3Kjpl2

[Medical Technology & Medical Device Network @MedicalTechMag]

TCT 2025: Elixir Medical’s arterial implant drops coronary events by nearly 50%

The DynamX Bioadaptor reduced risk of cardiovascular events across a two-year period.

https://t.co/5lDd1LINzK

[Radcliffe Cardiology @radcliffeCARDIO]

🎙️NEW #TCT2025 Interview 🌟 Prof David Erlinge discusses findings from the INFINITY-SWEDEHEART trial comparing the DynamX Bioadaptor to Resolute Onyx DES in 2,400 all-comer PCI patients

📽️👉 https://t.co/yQY1DO83fh
📊 Key findings demonstrated a 48% reduction in TLF rate, a significant reduction in target vessel failure and substantial benefits for high-risk patients with ACS after 6 months through 2 years in favour of the bioadaptor stent.

#PCI #Bioadaptor #DES #CardioTwitter

[Elixir Medical Corp @ElixirMed]

Congratulations Dr. Sahbi Fradi for your insightful presentation of “Calcium Modification in Complex PCI Using the LithiX HC-IVL System” at @TCTMD 2025.

This is a great example of resolving a large calcific nodule “with procedural efficiency” and “eliminating the need for capital equipment, particularly well suited for routine use in complex PCI scenarios.”

For more information on LithiX Hertz Contact IVL: https://t.co/tOXTu6j9B1

#TCT2025 #LithiX #IVL #Lithotripsy #PCI #ElixirMedical

[Cardiovascular News @CN_publishing]

Coronary bioadaptor (@ElixirMed) shows reduction in events compared to DES at two years, @DavidErlinge reports at #TCT2025 https://t.co/7Zk0d00EHJ